Results 271 to 280 of about 208,828 (307)
Some of the next articles are maybe not open access.
Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome
British Journal of Dermatology, 2016 F. Child, P. Ortiz‐Romero, R. Alvarez, M. Bagot, R. Stadler, M. Weichenthal, R. Alves, P. Quaglino, M. Beylot‐Barry, R. Cowan, L. Geskin, A. Pérez‐Ferriols, P. Hellemans, Y. Elsayed, C. Phelps, A. Forslund, M. Kamida, P. Zinzani +17 moresemanticscholar +1 more sourcePanobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.
The Lancet HIV, 2014 T. Rasmussen, M. Tolstrup, C. Brinkmann, R. Olesen, C. Erikstrup, A. Solomon, A. Winckelmann, S. Palmer, C. Dinarello, M. Buzón, M. Lichterfeld, S. Lewin, L. Østergaard, O. Søgaard +13 moresemanticscholar +1 more sourceA histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor‐β and vascular endothelial growth factor signalling
Liver international (Print), 2013 Yuqing Liu, Zhuo-qing Wang, Jiani Wang, W. Lam, Shuqin Kwong, Furong Li, S. Friedman, Shuyan Zhou, Qi Ren, Zhengshuang Xu, Xinge Wang, Ling Ji, Shoubin Tang, Hui Zhang, E. L. Lui, T. Ye +15 moresemanticscholar +1 more source
